All In Biotech

Drug Trial Radar · NCT00094653

MDX-010 Antibody, MDX-1379 Melanoma Vaccine, or MDX-010/MDX-1379 Combination Treatment for Patients With Unresectable or Metastatic Melanoma

A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination With a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2*0201-Positive Patients With Previously Treated Unresectable Stage III or IV Melanoma

Last checked: Nov 20, 2026Latest source record: Jul 11, 2011 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,783 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,783

Actual

Start

Sep 2004

Primary completion

Aug 2009

Study completion Oct 2009

Sponsor

Lead sponsor
Bristol-Myers SquibbBristol Myers Squibb (BMY)
Sponsor type
Industry
First posted
Oct 22, 2004

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine the safety and efficacy of MDX-010 (ipilimumab, BMS-734016) (anti-CTLA4) in combination with MDX-1379 (gp100, BMS-734019) in patients with previously treated, unresectable Stage III or IV melanoma. Survival time will be evaluated, as well as patient responses and time to disease progression. Eligible patients are those who in response to a single regimen containing interleukin-2 (IL-2), dacarbazine, and/or temozolomide, have 1) relapsed following an objective response (partial response/complete response \[PR/CR\]); 2) failed to demonstrate an objective response (PR/CR); or 3) could not tolerate such a regimen due to unacceptable toxicity. Patients will be randomized into one of three groups, and will receive one of the following treatments: MDX-010 alone, MDX-1379 alone, or MDX-010 in combination with MDX-1379.

Conditions

  • Melanoma
  • Metastases

Interventions

  • MDX-010 (anti-CTLA4) monoclonal antibodyDrug

    3mg/kg (intravenous \[iv\] infusion over 90 minutes), every 3 weeks for 4 doses

  • MDX-1379 (gp100) Melanoma Peptide VaccineBiological

    2mL (2 subcutaneous injections of 2 mL each, 1 to each thigh), every 3 weeks for 4 doses.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Survival (OS) (Time-to-Death) Difference Between MDX-010 in Combination With gp 100 Melanoma Peptide Vaccine Versus gp 100 Melanoma Peptide Vaccine AloneTime frame: From randomization until the end of the study, which was defined as the time at which 481 deaths were observed (264 weeks)

Locations

209 sites in 13 countries. Site status is shown where the registry gives one.

  • Arizona Cancer Center

    Tucson, Arizona

  • University Medical Center

    Tucson, Arizona

  • City of Hope National Medical Center

    Duarte, California

  • San Diego Cancer Center

    Encinitas, California

  • La Jolla Hematology and Oncology Medical Group

    La Jolla, California

  • Scripps Cancer Center

    La Jolla, California

  • Moores UCSD Cancer Center

    La Jolla, California

  • Pacific Shores Medical Group

    Long Beach, California

  • Cancer Institute Medical Group, Inc

    Los Angeles, California

  • The Angeles Clinic and Research Institute

    Los Angeles, California

  • USC/Norris Comprehensive Cancer Center

    Los Angeles, California

  • North County Oncology Medical Clinical, Inc.

    Oceanside, California

  • City of Hope Medical Group

    Pasadena, California

  • University of California, San Diego

    San Diego, California

  • St. Mary's Medical Center - Northern California Melanoma Center

    San Francisco, California

  • Cancer Institute Medical Group, Inc

    Santa Monica, California

  • San Diego Cancer Center

    Vista, California

  • Anschutz Cancer Pavilion

    Aurora, Colorado

  • Rocky Mountain Cancer Centers

    Aurora, Colorado

  • University of Colorado Health Sciences Center

    Aurora, Colorado

  • Rocky Mountain Cancer Centers

    Boulder, Colorado

  • Rocky Mountain Cancer Centers

    Colorado Springs, Colorado

  • Rocky Mountain Cancer Centers

    Denver, Colorado

  • University of Colorado Hospital

    Denver, Colorado

  • Rocky Mountain Cancer Centers

    Lakewood, Colorado

  • Rocky Mountain Cancer Centers

    Littleton, Colorado

  • Rocky Mountain Cancer Centers

    Lone Tree, Colorado

  • Rocky Mountain Cancer Centers

    Longmont, Colorado

  • Yale University School of Medicine - Oncology Outpatient Clinic

    New Haven, Connecticut

  • Mount Sinai Comprehensive Cancer Center at Aventura

    Aventura, Florida

  • Memorial Regional Cancer Center

    Hollywood, Florida

  • Shands Jacksonville

    Jacksonville, Florida

  • University of Florida/Jacksonville Faculty Clinic

    Jacksonville, Florida

  • Jackson Memorial Hospital & Clinics

    Miami, Florida

  • University of Miami Hospital & Clinics

    Miami, Florida

  • Mount Sinai Comprehensive Cancer Center

    Miami Beach, Florida

  • Mount Sinai Medical Center

    Miami Beach, Florida

  • M.D. Anderson Cancer Center Orlando

    Orlando, Florida

  • Palm Beach Cancer Institute

    Palm Beach Gardens, Florida

  • H. Lee Moffitt Cancer Center & Research Institute

    Tampa, Florida

Showing 40 of 209 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.